ヒト絨毛性ゴナドトロピンの世界市場レポート 2025年

ヒト絨毛性ゴナドトロピン市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で14億2,000万米ドルに成長します。予測期間の成長は、不妊症の発生率の増加、多嚢胞性卵巣症候群の急増、女性不妊症の増加、動物医療におけるHCGの使用量の増加に起因しています。予測期間における主な動向としては、妊娠検出の進歩、革新的な薬剤処方、技術統合、研究開発への注力、製品革新などが挙げられます。

不妊症の増加率は、今後数年間のヒト絨毛性ゴナドトロピン（hCG）市場の成長を促進すると予想されます。不妊症は、少なくとも1年間は避妊せずに性交を続けても妊娠できない状態と定義され、増加傾向にあります。その要因としては、出産の遅れ、ライフスタイルの変化、環境暴露、病状などが挙げられます。ヒト絨毛性ゴナドトロピン（hCG）は、不妊治療において、女性の排卵を刺激し、男性のテストステロン産生をサポートし、卵子の放出を促進し、不妊治療成績を改善するために利用されています。例えば、2023年4月、世界保健機関（WHO）は、不妊症が成人人口の約17.5％、すなわち世界のおよそ6人に1人の割合で発症していると報告し、身近で質の高い不妊治療が緊急に必要であることを強調しました。その結果、不妊率の上昇がヒト絨毛性ゴナドトロピン市場の成長を牽引しています。

ヒト絨毛性ゴナドトロピン市場の主要企業は、診断精度の向上、患者の転帰の改善、市場拡大のため、妊娠検出キットなどの革新的製品の開発に注力しています。妊娠検出キットは、体内のヒト絨毛性ゴナドトロピン（hCG）を検出することで妊娠を確認するように設計されています。例えば、米国の医療機器メーカーであるProov社は、2022年6月、早期妊娠検出用の新しいhCG検査薬を発表し、女性が生理予定日の6日前までに妊娠を確認できるようにしました。これらの検査は、尿中のhCGを99％を超える信頼性で同定し、女性が従来の検査よりも早く妊娠状態をモニターし、十分な情報に基づいた生殖に関する健康上の決定を下すための、信頼できる身近な方法を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ヒト絨毛性ゴナドトロピンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒト絨毛性ゴナドトロピン市場：成長率分析
• 世界のヒト絨毛性ゴナドトロピン市場の実績：規模と成長, 2019-2024
• 世界のヒト絨毛性ゴナドトロピン市場の予測：規模と成長, 2024-2029, 2034F
• 世界ヒト絨毛性ゴナドトロピン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒト絨毛性ゴナドトロピン市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 天然資源の抽出
• 組み換え技術
• 世界のヒト絨毛性ゴナドトロピン市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 女性不妊治療
• 精子減少症の治療
• 男性性腺機能低下症
• その他の治療領域
• 世界のヒト絨毛性ゴナドトロピン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のヒト絨毛性ゴナドトロピン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不妊治療クリニック
• 調査機関
• その他のエンドユーザー
• 世界のヒト絨毛性ゴナドトロピン市場天然資源抽出の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 妊婦の尿からの抽出
• 動物由来の抽出
• 世界のヒト絨毛性ゴナドトロピン市場、組換え技術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えHCG
• 治療用組換えHCG
• 診断用途向け組換えHCG

第7章 地域別・国別分析

• 世界のヒト絨毛性ゴナドトロピン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のヒト絨毛性ゴナドトロピン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒト絨毛性ゴナドトロピン市場：競合情勢
• ヒト絨毛性ゴナドトロピン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Janssen Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Sun Pharmaceutical Industries Limited
• Menarini Group
• Cipla Limited
• Hikma Pharmaceuticals plc
• Ferring Pharmaceuticals Inc.
• Intas Pharmaceuticals Ltd.
• Zydus Lifesciences Limited
• Lupin Limited
• Shenzhen Hepalink Pharmaceutical Group Co. Ltd.
• Scripps Laboratories Inc.
• Aspen Pharmacare Holdings Limited
• Corona Remedies Pvt Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒト絨毛性ゴナドトロピン市場2029：新たな機会を提供する国
• ヒト絨毛性ゴナドトロピン市場2029：新たな機会を提供するセグメント
• ヒト絨毛性ゴナドトロピン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy by the placenta shortly after embryo implantation in the uterus. It is essential for sustaining pregnancy by stimulating the corpus luteum in the ovary to produce progesterone, which maintains the uterine lining and prevents its breakdown.

The primary technologies for producing hCG are natural source extraction and recombinant technology. Recombinant technology involves combining DNA fragments from various organisms to create new genetic combinations. hCG is used in treating female infertility, oligospermia, male hypogonadism, and other conditions. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by fertility clinics, research institutions, and other users.

The human chorionic gonadotropin market research report is one of a series of new reports from The Business Research Company that provides human chorionic gonadotropin market statistics, including human chorionic gonadotropin industry global market size, regional shares, competitors with a human chorionic gonadotropin market share, detailed human chorionic gonadotropin market segments, market trends, and opportunities, and any further data you may need to thrive in the human chorionic gonadotropin industry. This human chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human chorionic gonadotropin market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the rise in the prevalence of hypogonadism in the geriatric population, increase in awareness toward HCG among healthcare professionals and patients, rise in popularity of fertility tourism, increase in the geriatric population, and increase in affordability and improvement in healthcare facilities.

The human chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the increasing incidence of infertility, surging prevalence of polycystic ovary syndrome, increasing female infertility, and rising usage of HCG in veterinary medicine. Major trends in the forecast period include advancements in pregnancy detection, innovative drug formulations, technological integration, focus on research and development, and product innovation.

An increasing rate of infertility is anticipated to propel the growth of the human chorionic gonadotropin (hCG) market in the coming years. Infertility, defined as the inability to conceive after at least one year of consistent, unprotected intercourse, is on the rise. Contributing factors include delayed childbearing, lifestyle changes, environmental exposures, and medical conditions. Human chorionic gonadotropin (hCG) is utilized in infertility treatments to stimulate ovulation in women and support testosterone production in men, facilitating egg release and improving fertility outcomes. For instance, in April 2023, the World Health Organization reported that infertility affects approximately 17.5% of the adult population, or roughly one in six people globally, underscoring the urgent need for accessible, high-quality fertility care. Consequently, the rising infertility rate is driving the growth of the human chorionic gonadotropin market.

Key players in the human chorionic gonadotropin market are focusing on the development of innovative products, such as pregnancy detection kits, to enhance diagnostic accuracy, improve patient outcomes, and broaden market reach. Pregnancy detection kits are designed to confirm pregnancy by detecting human chorionic gonadotropin (hCG) in the body. For example, in June 2022, Proov, a US-based medical equipment manufacturer, introduced new hCG tests for early pregnancy detection, enabling women to verify pregnancy up to six days before their expected period. These tests identify hCG in urine with a reliability rate exceeding 99%, providing a dependable and accessible method for women to monitor their pregnancy status earlier than traditional tests and make informed reproductive health decisions.

In September 2023, Lupin Limited, an India-based pharmaceutical company, acquired five brands from Menarini for an undisclosed sum. This acquisition aims to expand Lupin's portfolio and strengthen its position in key therapeutic areas by integrating five established brands from Menarini. Menarini Group, an Italy-based pharmaceutical and diagnostics company, offers services related to human chorionic gonadotropin (hCG).

Major companies operating in the human chorionic gonadotropin market are Pfizer Inc., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Janssen Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Menarini Group, Cipla Limited, Hikma Pharmaceuticals plc, Ferring Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Lupin Limited, Shenzhen Hepalink Pharmaceutical Group Co. Ltd., Scripps Laboratories Inc., Aspen Pharmacare Holdings Limited, Corona Remedies Pvt Ltd., Sanzyme Private Limited, Biocare Medical LLC, Lee BioSolutions Inc., MyBioSource Inc.

North America was the largest region in the human chorionic gonadotropin market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human chorionic gonadotropin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human chorionic gonadotropin market includes revenues earned by entities by providing services such as fertility treatments, hormone level monitoring, assisted reproductive technologies (ART), and pregnancy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Chorionic Gonadotropin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human chorionic gonadotropin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human chorionic gonadotropin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human chorionic gonadotropin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Natural Source Extraction; Recombinant Technology
• 2) By Therapeutic Area: Female Infertility Treatment; Oligospermic Treatment; Male Hypogonadism; Other Therapeutic Areas
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End User: Fertility Clinics; Research Institutions; Other End Users
• Subsegments:
• 1) By Natural Source Extraction: Extraction From Pregnant Women's Urine; Extraction From Animal Sources
• 2) By Recombinant Technology: Recombinant Hcg; Recombinant Hcg For Therapeutic Use; Recombinant Hcg For Diagnostic Applications
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Novartis AG; Bristol-Myers Squibb Company; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Chorionic Gonadotropin Market Characteristics

3. Human Chorionic Gonadotropin Market Trends And Strategies

4. Human Chorionic Gonadotropin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Human Chorionic Gonadotropin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Chorionic Gonadotropin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Chorionic Gonadotropin Market Growth Rate Analysis
• 5.4. Global Human Chorionic Gonadotropin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Chorionic Gonadotropin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Chorionic Gonadotropin Total Addressable Market (TAM)

6. Human Chorionic Gonadotropin Market Segmentation

• 6.1. Global Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural Source Extraction
• Recombinant Technology
• 6.2. Global Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Female Infertility Treatment
• Oligospermic Treatment
• Male Hypogonadism
• Other Therapeutic Areas
• 6.3. Global Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Human Chorionic Gonadotropin Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fertility Clinics
• Research Institutions
• Other End Users
• 6.5. Global Human Chorionic Gonadotropin Market, Sub-Segmentation Of Natural Source Extraction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Extraction From Pregnant Women's Urine
• Extraction From Animal Sources
• 6.6. Global Human Chorionic Gonadotropin Market, Sub-Segmentation Of Recombinant Technology, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Hcg
• Recombinant Hcg For Therapeutic Use
• Recombinant Hcg For Diagnostic Applications

7. Human Chorionic Gonadotropin Market Regional And Country Analysis

• 7.1. Global Human Chorionic Gonadotropin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Chorionic Gonadotropin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Chorionic Gonadotropin Market

• 8.1. Asia-Pacific Human Chorionic Gonadotropin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Chorionic Gonadotropin Market

• 9.1. China Human Chorionic Gonadotropin Market Overview
• 9.2. China Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Chorionic Gonadotropin Market

• 10.1. India Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Chorionic Gonadotropin Market

• 11.1. Japan Human Chorionic Gonadotropin Market Overview
• 11.2. Japan Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Chorionic Gonadotropin Market

• 12.1. Australia Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Chorionic Gonadotropin Market

• 13.1. Indonesia Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Chorionic Gonadotropin Market

• 14.1. South Korea Human Chorionic Gonadotropin Market Overview
• 14.2. South Korea Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Chorionic Gonadotropin Market

• 15.1. Western Europe Human Chorionic Gonadotropin Market Overview
• 15.2. Western Europe Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Chorionic Gonadotropin Market

• 16.1. UK Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Chorionic Gonadotropin Market

• 17.1. Germany Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Chorionic Gonadotropin Market

• 18.1. France Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Chorionic Gonadotropin Market

• 19.1. Italy Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Chorionic Gonadotropin Market

• 20.1. Spain Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Chorionic Gonadotropin Market

• 21.1. Eastern Europe Human Chorionic Gonadotropin Market Overview
• 21.2. Eastern Europe Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Chorionic Gonadotropin Market

• 22.1. Russia Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Chorionic Gonadotropin Market

• 23.1. North America Human Chorionic Gonadotropin Market Overview
• 23.2. North America Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Chorionic Gonadotropin Market

• 24.1. USA Human Chorionic Gonadotropin Market Overview
• 24.2. USA Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Chorionic Gonadotropin Market

• 25.1. Canada Human Chorionic Gonadotropin Market Overview
• 25.2. Canada Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Chorionic Gonadotropin Market

• 26.1. South America Human Chorionic Gonadotropin Market Overview
• 26.2. South America Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Chorionic Gonadotropin Market

• 27.1. Brazil Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Chorionic Gonadotropin Market

• 28.1. Middle East Human Chorionic Gonadotropin Market Overview
• 28.2. Middle East Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Chorionic Gonadotropin Market

• 29.1. Africa Human Chorionic Gonadotropin Market Overview
• 29.2. Africa Human Chorionic Gonadotropin Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Chorionic Gonadotropin Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Chorionic Gonadotropin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Chorionic Gonadotropin Market Competitive Landscape And Company Profiles

• 30.1. Human Chorionic Gonadotropin Market Competitive Landscape
• 30.2. Human Chorionic Gonadotropin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis

31. Human Chorionic Gonadotropin Market Other Major And Innovative Companies

• 31.1. Janssen Pharmaceuticals Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Sandoz International GmbH
• 31.4. Sun Pharmaceutical Industries Limited
• 31.5. Menarini Group
• 31.6. Cipla Limited
• 31.7. Hikma Pharmaceuticals plc
• 31.8. Ferring Pharmaceuticals Inc.
• 31.9. Intas Pharmaceuticals Ltd.
• 31.10. Zydus Lifesciences Limited
• 31.11. Lupin Limited
• 31.12. Shenzhen Hepalink Pharmaceutical Group Co. Ltd.
• 31.13. Scripps Laboratories Inc.
• 31.14. Aspen Pharmacare Holdings Limited
• 31.15. Corona Remedies Pvt Ltd.

32. Global Human Chorionic Gonadotropin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Chorionic Gonadotropin Market

34. Recent Developments In The Human Chorionic Gonadotropin Market

35. Human Chorionic Gonadotropin Market High Potential Countries, Segments and Strategies

• 35.1 Human Chorionic Gonadotropin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Chorionic Gonadotropin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Chorionic Gonadotropin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer